CD30, also known as TNFRSF8 (TNF receptor superfamily member 8), [5] is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker. This receptor is expressed by activated, but not by resting, T and B cells.

Immunohistochemical stains are performed and the cells are negative for CD30, while CD3 and CD20 highlight small and mature T and B lymphocytes, respectively. Histologic sections of the right breast capsule show a fibrinous breast capsule with scattered small and …

CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor marker that is found on the surface of specific cells in the body, …

2017年9月8日 · CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma...

In this review, we describe current evidence for anti-CD30 therapy in lymphoma, discuss ongoing controversies and data gaps, and provide perspectives on the direction of anti-CD30 therapy in the future. The development of brentuximab vedotin has altered the treatment approach for patients with cHL.

CD30 was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand (CD30L) established these proteins as members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor (TNF) superfamilies, respectively.

CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma.

Cluster determinant 30 (CD30) has been recognized since the 1980s by a monoclonal antibody (Ki-1) as an epitope of a membrane protein highly expressed on Reed–Sternberg and Hodgkin’s lymphoma cells [9–11] and infrequently on normal blood lymphocytes.

2016年12月2日 · We aimed to study the expression of CD30 in a large cohort of the novo DLBCL patients homogeneously treated with R-CHOP or R-CHOP-like protocols to evaluate its correlation with clinical and biological characteristics at diagnosis and its impact in …

2019年8月8日 · We discuss 3 distinct presentations of primary cutaneous CD30 + lymphoproliferative disorder and present recommendations for a multidisciplinary team approach to diagnosis, evaluation, and management of these conditions in …